Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 5, pp 1075–1079 | Cite as

Factors associated with prescribing restriction on oncology formulary drugs in Malaysia

  • Omotayo FatokunEmail author
  • Michael N. Olawepo
Short Research Report
  • 112 Downloads

Abstract

Background Drugs listed on formularies are often subjected to a variety of utilization restriction measures. However, the degree of restriction is influenced by multiple factors, including the characteristics and attributes of the listed drugs. Objective To identify the factors that are associated with the levels of prescribing restriction on oncology formulary drugs in Malaysia. Setting Oncology formulary in Malaysia. Method The Malaysia Drug Code assigned to each of the drug products on the Malaysia Ministry of Health (MOH) drug formulary was used to identify oncology drugs belonging to WHO ATC class L (antineoplastic and immunomodulating agents). Main outcome measures Categories of prescribing restrictions, therapeutic class, drug type, administration mode, number of sources and the post-approval use period. Results Oncology drugs having a shorter post-approval use period (p < 0.001), biologic oncology drugs (p = 0.01) and oncology drugs belonging to immunosuppressant therapeutic class (p = 0.03) were all significantly associated with a greater likelihood of being subjected to a higher level of prescribing restriction. Conclusion This study suggests that safety concerns, costs and potentials for inappropriate use were the important considerations influencing a higher level of prescribing restriction placement on oncology drugs in the Malaysia MOH drug formulary.

Keywords

Decision-making Formulary drugs Formulary management Formulary restriction Malaysia Oncology drugs 

Abbreviations

MOH

Ministry of Health

MDC

Malaysia Drug Code

WHO

World Health Organization

Notes

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of interest

The authors [Omotayo Fatokun, Michael N. Olawepo] declare that they have no conflicts of interest.

Supplementary material

11096_2016_372_MOESM1_ESM.pdf (88 kb)
Supplementary material 1 (PDF 87 kb)

References

  1. 1.
    Chase KA. Medication management. In: Holdford DA, Brown TR, editors. Introduction to hospital and health-system pharmacy practice. Bethesda: American Society of Health-System Pharmacists; 2010. p. 59–80. (ISBN: 978-1-58528-237-1).Google Scholar
  2. 2.
    Blumenthal D, Herdman, R. Description and analysis of the VA national formulary. Washington, D.C.: National Academy Press; 2000. (ISBN: 0-309-56964-8).Google Scholar
  3. 3.
    Schiff G, Galanter W, Duhig J, Koronkowski M, Lodolce A, Pontikes P, et al. A prescription for improving drug formulary decision making. PLoS Med. 2012;. doi: 10.1371/journal.pmed.1001220.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Hussain S. Drug control and formulary management in Malaysia. Value Health. 2008;11:S158–9. doi: 10.1111/j.1524-4733.2008.00381.x.CrossRefPubMedGoogle Scholar
  5. 5.
    Ministry of Health Malaysia. Ministry of health drug formulary No. 3/2014 [Internet]; 2014 Dec [cited 2015 Jan 21]. http://www.pharmacy.gov.my/v2/en/apps/fukkm. Acceesed 21 Jan 2015.
  6. 6.
    Norusis M. SPSS 13.0 Statistical procedures companion. New Jersey, NJ: Prentice Hall; 2005. (ISBN: 0-13-186539-0).Google Scholar
  7. 7.
    Durán-García E, Santos-Ramos B, Puigventos-Latorre F, Ortega A. Literature review on the structure and operation of pharmacy and therapeutics committees. Int J Clin Pharm. 2011;33:475–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Patel BN, Audet PR. A review of approaches for the management of specialty pharmaceuticals in the United States. Pharmacoeconomics. 2014;32:1105–14.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yazdany J, Dudley RA, Chen R, Lin GA, Tseng CW. Coverage for high-cost specialty drugs for rheumatoid arthritis in medicare part D. Arthritis Rheumatol. 2015;67:1474–80.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Trevillian P. Immunosuppressants—clinical applications. Aust Prescr. 2006;29:102–8.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  1. 1.Department of Clinical Pharmacy, Faculty of Pharmaceutical SciencesUCSI UniversityKuala LumpurMalaysia
  2. 2.Tesco PharmacyGallagher Retail ParkScunthorpeUK

Personalised recommendations